Utah Medical Products (UTMD) Depreciation & Amortization (CF) (2010 - 2026)

Utah Medical Products' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $211000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 5.5% year-over-year to $211000.0 in Q1 2026; TTM through Mar 2026 was $837000.0, a 8.14% increase from a year earlier, with the FY2025 full-year figure at $826000.0, up 13.15% from the prior year.
• Depreciation & Amortization (CF) was little changed at $211000.0 in Q1 2026 per UTMD's latest filing, from $212000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $212000.0 in Q4 2025 and bottomed at $149000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $158000.0 (2022), against an average of $176588.2.
• Across the five-year window, Depreciation & Amortization (CF) retreated 8.59% in 2022 and soared 30.97% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $158000.0 in 2022, then changed by 0.0% to $158000.0 in 2023, then grew by 26.58% to $200000.0 in 2024, then grew by 6.0% to $212000.0 in 2025, then fell by 0.47% to $211000.0 in 2026.
• Per Business Quant, the three latest UTMD Depreciation & Amortization (CF) figures stand at $211000.0 (Q1 2026), $212000.0 (Q4 2025), and $209000.0 (Q3 2025).